Lowey Dannenberg is prosecuting a class action, on behalf of a class of third-party payers, alleging that Ranbaxy, one of the world’s largest generic pharmaceutical manufacturers, prevented competition among various generic drugs by adopting a long-term fraudulent scheme to obtain “first-to-file” status for their generic drugs based on false and deceptive representations made to FDA.